Intellipharmaceutics International Inc. (IPCI): Bernstein, Just be forewarned. Everythi...

Bernstein, Just be forewarned. Everything, you point

Samsa · 2018-11-08T12:47:40.3630000Z

Bernstein, Just be forewarned. Everything, you point out as being a good thing about this stock is what the company has had as a good thing going for it, for years. Which, is why people like myself have a cost average of around $9 to $10 a share. So how did all those good things do for us? Mark my words, you think it can't get any worse and 53 cents is a good price to get in. He can do another RS. Your 53 cents becomes $5.30 and we get traded back down to 50 cents again because he never follows through on anything and just continues to spend money. The fact that 17 million shares were already paid for at a penny compared to your 53 cents, that can easily happen.

Play Episode

5min

Proactive - Interviews for investors

Orion Minerals CEO on Prieska & Okiep DFS milestones as company enters next phase

Orion Minerals Ltd (ASX:ORN, JSE:ORN) managing director and CEO Errol Smart talked with Proactive's Stephen Gunnion about the completion of definitive feasibility studies (DFS) for both the company’s flagship Prieska copper-zinc project and the Flat Mines project at its Okiep copper project. Smart described this as a pivotal moment, noting, “It’s taken us eight years now to put them together… but it's really a great outcome for us.” The studies confirm robust development pathways for both operations in South Africa's Northern Cape, with both projects fully permitted and development-ready. Smart said Orion is in a unique position globally, with capital intensity figures below key industry benchmarks. The combined production profile is expected to deliver 30,000 tonnes of copper annually at around $9,500 per tonne capital intensity, placing the company in the lower quartile of the cost curve. The Prieska project will follow a two-phase development plan, with a modest $25 million start-up operation set to begin production within 13 months, followed by a ramp-up to full-scale output. Smart also confirmed that discussions are underway with strategic partners, including the Industrial Development Corporation and offtake-related financiers. He highlighted that smelters and traders are actively seeking long-term copper supply, saying, “We represent a very interesting opportunity for them, with certainty.” Visit Proactive’s YouTube channel for more company updates and interviews. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #OrionMinerals #CopperMining #PrieskaProject #OkiepProject #BaseMetals #MiningInvestment #FeasibilityStudy #SouthAfricaMining #CopperProduction #ZincProduction

Proactive - Interviews for investors

Immunic CMO discusses significance of MS Awareness Month; progress with treatment

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company’s work in multiple sclerosis (MS) as MS Awareness Month concludes. Muehler discussed the importance of continued research funding and the community’s role in advancing treatment. He highlighted the company’s lead asset, vidofludimus calcium, which is in advanced-stage clinical trials. Results from the phase 2 EMPHASIS trial in relapsing-remitting MS showed a reduction of about three-quarters of new MRI lesions compared to placebo. Muehler said, “This is a very good value,” and pointed to biomarker data showing a strong, dose-linear suppression of neurofilament — a sign of nerve cell damage. A phase 3 program involving more than 2,000 patients is now underway, with data expected in 2026. In progressive MS, Immunic is close to reporting data from its phase 2 CALLIPER trial, having already seen positive biomarker signals at 24 weeks. Muehler addressed patients’ fears of disability, stressing the company’s commitment to tackling "progression independent of relapse activity (PIRA)", a key unmet need. He emphasized vidofludimus calcium’s dual mechanism — both anti-inflammatory and neuroprotective — and its potential to become the first oral drug targeting the full spectrum of MS. To hear more insights from Immunic and other biotech leaders, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #ImmunicTherapeutics #MultipleSclerosis #MSAwarenessMonth #vidofludimuscalcium #MSTreatment #ClinicalTrials #Neuroprotection #MSResearch #BiotechNews #ProgressiveMS #RelapsingMS #PIRA #DrugDevelopment

Proactive - Interviews for investors

Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInve

Proactive - Interviews for investors

4GLOBAL CEO discusses expansion of Sport England deal for wider insights

4GLOBAL PLC (AIM:4GBL) CEO Eloy Mazon talked with Proactive's Stephen Gunnion about the company’s expanded agreement with Sport England. The updated contract deepens 4GLOBAL’s role in delivering data-led insights to support increased sports participation across England, extending beyond facilities to include outdoor and informal activity spaces. Mazon explained that this new phase builds on a successful four-year partnership which helped boost participation by over 30%. “We like to think we play a very significant part in achieving those outcomes,” he said, referring to the impact of 4GLOBAL’s data platform on investment decisions in grassroots sports. Now, Sport England is shifting focus to track physical activity beyond formal facilities, such as cycling paths and running tracks. 4GLOBAL’s recently launched insight platform plays a key role by integrating multiple datasets to generate predictive insights. Mazon said, “This contract…places us at the centre of sport and physical activity in England.” He added that the broader ecosystem engagement—covering everything from local authorities to gym operators—offers not only data value for Sport England but commercial opportunities for 4GLOBAL. Mazon also highlighted the strategic value of this multi-year, multi-million-pound contract as part of the company’s move toward recurring revenue and EBITDA growth. “The focus for us going forward is to really grow EBITDA, because that provides us with that free cash flow…to invest in growth,” he noted. For more CEO interviews and market updates, head to Proactive's YouTube channel. Don’t forget to like this video, subscribe to the channel, and turn on notifications for the latest updates. #4GLOBAL #SportEngland #DataAnalytics #PhysicalActivity #GrassrootsSports #SportsInvestment #ARRGrowth #EBITDA #SmartData #ProactiveInvestors #UKSport

Followers	8
Posts	1427
Boards Moderated	0
Alias Born	06/30/2016

Volume:	-
Day Range:
Bid:	0.07
Ask:	0.12
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

IPCI Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free